While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

The findings highlight how the integration of glucagon-like peptide-1 (GLP-1) medications for weight loss is reshaping the Aesthetics market, fueling significant growth for practices across the ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

Medspas are leading the charge in offering GLP-1 treatments, with 60% of medspas in the U.S. now providing these services, compared to 35% of aesthetic physician offices. Average spend per patient ...